 We performed a 6-week, 4-group, parallel, randomized, double-blind, double-dummy, clinical trial in 60 patients with perennial allergic rhinitis. After an initial screening with an allergy questionnaire and skin puncture testing to confirm an allergic response to a perennial allergen cat, dog, dust mite, indoor mold, qualified individuals were randomized into 1 of 4 treatment groups. The 4 groups received the following treatments: placebo, OXY 0.05, 2 puffs in each nostril every evening, FF nasal spray 110 mg per day, and FF nasal spray plus OXY FFOXY. All participants received 2 nasal sprays at night, with 1 spray containing FF or its placebo, the other oxymetazoline or its placebo. The nasal sprays were labeled with participant code numbers, and the investigator assigned participants in a sequential randomized fashion to a study code number in blocks of 4. Dropouts were replaced until 60 subjects were randomized. Replacement subjects were assigned the next sequential treatment. Thus, the number of subjects in each group was not exactly 15. 